https://www.selleckchem.com/pr....oducts/bevacizumab.h
) on the growth of CRC cells/xenografts in vitro and in vivo. Moreover, PRMT5 and EZH2 were found to be significantly elevated and associated with poor prognosis in CRC patients. Conclusion PRMT5 functionally associates with EZH2 to promote CRC progression through epigenetically repressing CDKN2B expression. Thus, our findings raise the possibility that combinational intervention of PRMT5 and EZH2 may be a promising strategy for CRC therapy.Rationale The compensatory activation of the renin-angiotensin system (RAS) after myocardial
Like
Comment
Share
